Immunovia: First NCI Collaboration In The Diabetes Opportunity
Edison | Dec 20, 2016 06:16AM ET
Immunovia (ST:IMMNOV) has taken key steps in both opportunities being pursued for its IMMray PanCan-d test for the early detection of pancreatic cancer. In diabetes, a collaboration with the Early Detection Research Network (EDRN), part of the US National Cancer Institute (NCI), is an important step forwards as it could lead to the start of the required clinical study. Diabetes is the larger of the two indications with 3.4 million newly diagnosed diabetes patients every year in the US and EU. In high-risk pancreatic cancer patients, Immunovia has now started a prospective clinical trial, as expected. This is a smaller opportunity (c 200k patients) but could generate initial revenues in 2018. Our valuation remains SEK155.2/share.
Immunovia delivers agreement with NCI
Immunovia has made important first steps towards its strategy of pursuing new onset diabetic patients by signing a memorandum of understanding (MoU) with the NCI EDRN. The goal of the collaboration with EDRN is to validate biomarkers to improve early diagnosis of pancreatic cancer, in particular in patients over 50 years old with new onset diabetes. These patients have eight times more risk to develop pancreatic cancer. We believe that this collaboration could lead to the start of a formal clinical trial to test IMMray PanCan-d in this population in order to gain regulatory approvals for the test. We anticipate that any such trial could involve 5,000 to 10,000 patients, analysed at least twice a year over three years. Immunovia recently raised c SEK218.6m to advance the diabetic opportunity.
To read the entire report Please click on the pdf File Below
Get The News You Want
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.